Ghrelin in Obesity and Endocrine Diseases.

[Mike Bikov]

Mol Cell Endocrinol. 2011 Feb 20. [Epub ahead of print]
Ghrelin in Obesity and Endocrine Diseases.

Scerif M, Goldstone AP, Korbonits M.

Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.
Abstract

Ghrelin shows orexigenic effect through its action on the hypothalamic appetite-regulating pathways while in the periphery increases adipose tissue accumulation, and has a diabetogenic effect on the liver and pancreas. The availability of nutrients in the gut and ghrelin's effect on the growth hormone axis is intricately connected with the overall regulation of metabolism. Adenosine monophosphate-activated protein kinase (AMPK) has been suggested as one of the mediators of ghrelin's effects. Plasma ghrelin levels are dependent on body mass index as well as food intake patterns. Ghrelin levels are in general reduced in obese individuals and in subjects with insulin resistance. In contrast to other forms of obesity, patients with Prader-Willi syndrome (PWS) display high levels of ghrelin, reduced visceral adiposity and relative hypoinsulinemia. Relationships between obesity and common genomic variants of GHRL and GHS-R genes have been studied. The role of changing ghrelin levels following bariatric surgery is a debated issue but may contribute to the weightreducing effect of the procedures. Altered ghrelin levels have been observed in Cushing's syndrome and thyroid disease probably due to the secondary insulin resistance in these subjects.
Copyright © 2011. Published by Elsevier Ireland Ltd.

PMID: 21345363 [PubMed - as supplied by publisher]

🤪
​